Neu auf wallstreet:online?
Jetzt registrieren | Login
x
Benutzername:

Passwort:

Angemeldet bleiben
Passwort vergessen?

Eckert & Ziegler BEBIG has recently installed the latest generation MultiSource® device in the leading private clinic in Bogota, Colombia

Nachrichtenquelle: GlobeNewswire
 |  28.09.2011, 17:42  |  1091 Aufrufe  |   | 


September 28, 2011

Seneffe, Belgium, September 28, 2011,  Eckert & Ziegler BEBIG, a global leader in
brachytherapy, has recently installed the first MultiSource® HDR (High Dose
Rate) afterloader of the latest generation in the Centro de Control de Cancer
LTDA in Bogota, Colombia. The system is the first of its kind worldwide and it
is already used effectively in the treatment of cancer patients.

Centro de Control de Cancer is one of leading private medical institutions in
Colombia and a renowned leader in the implementation of high technology in
cancer treatment in South America. Opened in 1993, it is run by distinguished
physicians: Armando Gaitan, Juan Carlos Arbelaez, Felipe Torres, Ricardo
Cendales, Ivan Bobadilla and medical physicists: Jaider Vasques, Ricardo Español
and Helbert Cortes. The centre is equipped with the latest technology for
treating cancer including three linear accelerators and one Co-60 (Cobalt 60)
machine. The new MultiSource® HDR afterloader complements the existing
therapeutic line ideally. In addition to the MultiSource®, Centro de Control de
Cancer is using HDRplusTM3.0, the latest version of Eckert & Ziegler BEBIG´s
treatment planning system, an intuitive software for precise and efficient HDR
treatment planning, which provides its users with functions that considerably
simplify and accelerate their preparation of the treatment plan.

"We have increased our productivity using the MultiSource® afterloader,
considering that we have a reliable and fast device, accompanied by an excellent
technical support and easy-to-use planning software. This has been highly
appreciated by our physicians and physicists. Plans to implement image-guided
brachytherapy in gynecological tumors and performing in vivo dosimetry are
already on their way", said doctor Ricardo Cendales, six weeks after the
installation of the MultiSource® afterloader in the clinic.

According to the doctors and physicists from the Centro de Control de Cancer in
Bogota the innovative medical technology like MultiSource® afterloader
contributes considerably to the facilitation of the clinical practice:  "This is
a very good example of the optimal results of a good relationship between the
equipment developers and the clinical practitioners in order to make
radiotherapy equipment easier, more precise and user friendly." (Armando Gaitan,
physician).

Centro de Control de Cancer treats every day a large number of patients with
brachytherapy. The three most common pathologies treated with HDR are
gynecological, prostate and esophagus cancer. The clinic is dedicated to helping
patients with limited financial resources. As a part of social policy, a special
foundation was created to support this disadvantaged group of patients and to
promote higher education to radiation therapy personnel at all levels.

The medical experts from Bogota see in the use of the MultiSource® afterloader
an important step towards the fight against cancer and better quality of life
for the patients: "The clinical introduction of a precise and safe afterloader
like MultiSource® in combination with an innovative treatment planning system
which provides more complex and accurate algorithms to the patients dose
calculation is a perfect reflection of synergy between science and technology to
improve patients´ quality of  life"  stated Jaider Vasquez, medical physicist at
the Centro de Control de Cancer.

Eckert & Ziegler BEBIG´s MultiSource® device can be used with either an iridium-
192 or a cobalt-60 source. Both sources are ideally suited to treat
gynecological, prostate, breast, esophageal and lung cancers, as well as some
cancers of the head and neck. Centro de Control de Cancer has purchased the
MultiSource® afterloader with an iridium-192 source.

"Eckert & Ziegler BEBIG is the only company offering a multiple source HDR
afterloader. With our proprietary Co-60 MultiSource® device, we offer a cost-
effective solution in the fight against cancer. We have already installed over
170 MultiSource® systems worldwide, and more than 20,000 patients were treated
with our systems in 2010, " commented Eckert & Ziegler BEBIG´s Managing Director
Dr. Edgar Löffler.

According to the World Health Organization, cancer rates will continue to rise.
More than 70 percent of all cancer deaths occur in low and middle income
countries. One reason for this grim death toll is the high cost of the equipment
for conventional external beam therapy. Investments for brachytherapy are much
lower. When used with Co-60, the new MultiSource®HDR afterloader reduces
operating costs by up to 80 percent compared to an Ir-192 system.

About Eckert & Ziegler BEBIG

Contributing to saving lives!

Eckert & Ziegler BEBIG is a European-based group active in the medical device
segment of the health care industry.

Eckert & Ziegler BEBIG´s core business is the treatment of cancer using
brachytherapy, a special form of radiation therapy.

Eckert & Ziegler BEBIG is a leader in brachytherapy in Europe. The company
headquarters are in Belgium, with a production facility in Germany and
subsidiaries throughout Europe and in India. In addition, Eckert & Ziegler BEBIG
has a worldwide network of distributors and agents to support the international
marketing of its product line.

The company´s products and equipment are intended for use by oncologists,
radiologists, urologists, and medical physicists.

Eckert & Ziegler BEBIG employs more than 150 people. The company has been listed
on the Euronext stock exchange since April 1997 (Euronext: EZBG; Reuters:
EZBG.BR; Bloomberg: EZBG:BB).


Contact
Paul-Emmanuel Goethals
Investor Relations
Tel.: +32.64.520.808
Email:ir@bebig.eu
Website:www.bebig.eu


This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Eckert & Ziegler BEBIG via Thomson Reuters ONE

[HUG#1550591]

Wertpapiere des Artikels:
BE0003689032

Wertpapier: Eckert-Ziegler Bg

Themen: Iridium


Schreibe Deinen Kommentar

 

Disclaimer

Enthaltene Werte

WertpapierKursZeitPerf. in %
1,75
09:01 
-2,72

Nachrichtenquelle

Weitere Nachrichten des Autors

TitelLeser
263
202
195
194
186
TitelLeser
500
440
426
408
399
TitelLeser
779
764
725
642
566
TitelLeser
11034
10656
8254
7880
7150

Top Nachrichten aus der Rubrik